Access and Evidence
Into pharma's roaring twenties
A new decade is here. And despite the incredible science, pharma is ill-equipped.
More Articles
Patients and Medical
Scaling patient engagement for deeper insights and better outcomes
Scaling patient engagement offers a cascade of benefits if only pharma can gather the right insights
Patients and Medical
Pharma’s new ally: The caregiver
Pharma has only just started thinking about how engaging with caregivers could unlock a range of valuable insights
Access and Evidence
Advancing RWE together with academia
Pharma can realise the potential of RWE faster by collaborating more effectively with academia but first it must build trust
Medical
Invest in MSLs to reap bigger gains
To get the most from MSLs pharma needs to invest, measure and empower
Clinical
Telemedicine: The future of clinical trials?
There is a new surge of interest in telemedicine’s potential to optimize clinical trials, but is this what patients want?
Patients and Medical
Patients united: Bringing the patient voice to genetics research
Parkinson’s disease genetic research has a powerful force to hand – an army of patients
Multichannel
Five eye-openers from the MIT Healthcare Panel
Modern pharma should not underestimate the importance of experience and culture in this age of innovation in R&D and data science
Access and Evidence
Prescription drug pricing: The times they are a changin’
The political mood in the US on drug pricing at a national and state level is putting the pressure on pharma to demonstrate value
Commercial
Has direct to consumer marketing in pharma had its day?
Outmoded and cliched DTC campaigns may be harming not helping pharma in the US